Pascal Deschatelets - 17 Jan 2025 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Scientific Officer
Signature
/s/ David Watson, attorney-in-fact for Pascal Deschatelets
Issuer symbol
APLS
Transactions as of
17 Jan 2025
Net transactions value
-$22,469
Form type
4
Filing time
21 Jan 2025, 16:02:18 UTC
Previous filing
14 Jan 2025
Next filing
23 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Sale $22,469 -750 -0.07% $29.96 1,137,445 17 Jan 2025 Direct F1
transaction APLS Common Stock Award $0 +15,045 +1.3% $0.000000 1,152,490 21 Jan 2025 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 16, 2025.
F2 This represents a Restricted Stock Unit award granted on January 21, 2025 that vest 25% annually over four years from grant date subject to continued service.